Oncorus raises $61M in Series A

What does Oncorus do?

Oncorus, is a immuno Oncology firm which is developing next gen immunotherapy platform of cancer related viruses to treat many tumor types including aggressive and highly malignancy cancers like GBM- Glioblastoma multiforme. This lean early stage biotech company is the next gen platform for treating cancer.

How much Oncorus was funded?

The company raised £4M in Series A on December 16, 2016 from Astellas Venture Management.

Previous funding

$57M in Series A on July 19, 2016  from MPM Capital, Deerfield, Arkin Bio Ventures, Long March Investment Fund,  Celgene, SunStates Fund and Excelyrate Capital.

What is next for Oncorus?

The company plans on using the latest funding raised for advancing its immunotherapy platform using its next gen oHSV- Oncolytic Herpes Simplex Virus. This platform would become a new paradigm in treating cancer. The company is excited at partnering with the lead group of investors for supporting its experienced team of management and world class researchers in this field. The company is a leader in corporate philanthropy, and has pledged to donate a part of its product sales for funding promising cancer research and for supporting cancer care in the world. The funding will also help the company in discovering innovative therapies which will benefit the patients in need and the physicians who treat them. The company has some patent rights from the University of Pittsburgh based on the works of renowned scientists Paola Grandi, Ph.D., and Joseph Glorioso III, Ph.D. The company’s current lead is in its pre-clinical development for GBM. It has plans for accelerating the development of pipeline programs in other cancer forms.

More about Oncorus

Oncorus was founded on April 1, 2015. It has its headquarters in Cambridge, Massachusetts. The company was founded by Mitch Finer, MPM Managing Director , a well-known biotech entrepreneur.